109 related articles for article (PubMed ID: 21971230)
1. [Novel therapeutics for myelodysplastic syndromes].
Tohyama K
Rinsho Ketsueki; 2011 Oct; 52(10):1535-43. PubMed ID: 21971230
[No Abstract] [Full Text] [Related]
2. [Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Miyazawa K
Rinsho Ketsueki; 2008 Oct; 49(10):1358-67. PubMed ID: 18833920
[No Abstract] [Full Text] [Related]
3. Improving the outlook for myelodysplastic syndrome.
Brower V
J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
[No Abstract] [Full Text] [Related]
4. Myelodysplastic syndromes (MDS).
Klimek V
Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
[No Abstract] [Full Text] [Related]
5. How I treat patients with myelodysplastic syndromes.
Stone RM
Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969
[No Abstract] [Full Text] [Related]
6. [Molecular target therapy for myelodysplastic syndrome].
Morita Y; Tanaka H; Matsumura I
Nihon Rinsho; 2012 Nov; 70 Suppl 8():508-12. PubMed ID: 23513892
[No Abstract] [Full Text] [Related]
7. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
8. New agents in the treatment of MDS.
List AF
Clin Adv Hematol Oncol; 2005 Nov; 3(11):832-4. PubMed ID: 16491623
[No Abstract] [Full Text] [Related]
9. [Myelodysplastic syndromes: therapeutic advances and promising future].
Nomdedeu B
Med Clin (Barc); 2008 Oct; 131(13):500-2. PubMed ID: 19007578
[No Abstract] [Full Text] [Related]
10. Azacitidine.
Issa JP; Kantarjian HM; Kirkpatrick P
Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
[No Abstract] [Full Text] [Related]
11. [Novel therapeutic agents for myelodysplastic syndrome].
Ishikawa T
Rinsho Ketsueki; 2009 Oct; 50(10):1553-9. PubMed ID: 19915366
[No Abstract] [Full Text] [Related]
12. MDS: unraveling the mystery.
Rizzieri DA
Blood; 2012 Dec; 120(25):4906-8. PubMed ID: 23243154
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of myelodysplastic syndromes.
Galili N; Raza A
Expert Opin Pharmacother; 2010 Aug; 11(11):1889-99. PubMed ID: 20486832
[TBL] [Abstract][Full Text] [Related]
14. Use of hypomethylating agents in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
[TBL] [Abstract][Full Text] [Related]
15. Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
DeZern AE
Hematology Am Soc Hematol Educ Program; 2015; 2015():308-16. PubMed ID: 26637738
[TBL] [Abstract][Full Text] [Related]
16. New therapeutics for myelodysplastic syndromes.
List AF
Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
[TBL] [Abstract][Full Text] [Related]
17. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Steensma DP; Stone RM
Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes: introduction.
Sloand EM
Semin Hematol; 2008 Jan; 45(1):1-2. PubMed ID: 18179962
[No Abstract] [Full Text] [Related]
19. Decitabine (Dacogen) for myelodysplastic syndromes.
Med Lett Drugs Ther; 2006 Nov; 48(1247):91-2. PubMed ID: 17082739
[No Abstract] [Full Text] [Related]
20. Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Galili N; Raza A
Best Pract Res Clin Haematol; 2009 Jun; 22(2):223-37. PubMed ID: 19698930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
